The therascreen KRAS RGQ PCR Kit, developed by England-based QIAGEN Manchester, is designed to provide information about the KRAS gene mutation in patients whose colorectal cancer has spread to other parts of their body. Studies have found that Eribitux is not effective in those who have the mutation.
FDA also approved a new indication for Erbitux for use in combination with FOLFIRI, chemotherapy drugs consisting of irinotecan, 5-fluorouracil, and leucovorin, as a first-line treatment in patients with metastatic colorectal cancer who have epidermal growth factor receptor-expressing, and KRAS wild-type (no mutations) tumors.
Erbitux is co-marketed by Bristol-Myers Squibb and Eli Lilly and Co.
Related Articles on FDA Approvals:
r4 Vascular Receives FDA Clearance for PTA Balloon
Intrinsic Medical Imaging Receives FDA Clearance for 3D Imaging Workstation
Teleflex Receives FDA Clearance for Peripherally Inserted Central Catheter
